...the past three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s...
...compound #), AG-014699 (Former compound #), rucaparib (Generic) Alecensa, Alecensaro, alectinib (AF802, CH5424802, RG7853, RO5424802) Piqray, alpelisib (BYL719) Foundation Medicine Inc. Clovis...

...million series C round in August via its Roche Venture Fund. The fund also invested in Foundation Medicine Inc.’s...

...the way Guardant Health Inc. (NASDAQ:GH) and Foundation Medicine Inc....

...of genomic profiling company Foundation Medicine Inc. prior to its acquisition by Roche (SIX:ROG; OTCQX:RHHBY) in 2018. Foundation Medicine...

...successful launch and one that ensures the right patients get access to the therapy. “Through Foundation Medicine...
...“Success in Lung Cancer Niches Will Hinge on Access to Next-Gen Sequencing” ). Through Roche’s Foundation Medicine...

...with a high mutational burden -- tumors with at least 10 mutations/megabase as assessed using Foundation Medicine Inc.’s...

...cancer patients with a certain c-MET mutation. Tabrecta and its FoundationOne CDx companion diagnostic from Foundation Medicine Inc....

...who has served as interim CEO since September. Civik was chief commercial officer of the Foundation Medicine Inc....

...Troy Cox will become chairman on March 1, succeeding Antoine Duchateau. Cox was CEO of Foundation Medicine Inc....

...Riley was VP, general manager of Catalent Biologics; Boerman was president of Aesica Pharmaceuticals Ltd. Foundation Medicine Inc....
...CRISPR-based gene therapies for eye diseases. BioCentury Staff Disarm Therapeutics Inc. Acacia Pharma Group plc Twist Bioscience Corp. Flatiron Health Inc. Foundation Medicine Inc. BioNTech...